GET DAILY SIGNALSNutriband Inc. (NTRB): Assessing the Potential of Its Abuse-Deterrent Patch Technology
Key Takeaways
- NTRB is the Nasdaq listing for Nutriband Inc., a clinical-stage developer of transdermal pharmaceutical patches headquartered in Orlando, Florida.
- The company's lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl patch for chronic pain, with related pipeline programs for buprenorphine and methylphenidate.
- Nutriband generates modest revenue through two subsidiaries providing contract manufacturing and contract research services, while its pharmaceutical programs remain pre-revenue and require substantial additional funding.
- As an early-stage drug developer, Nutriband has a history of net losses and carries significant regulatory, clinical, and financing risk typical of pre-approval biopharmaceutical companies.
Introduction
Nutriband Inc. is a specialty pharmaceutical company focused on developing transdermal drug delivery products, with an emphasis on abuse-deterrent versions of existing opioid and stimulant patches. Investors follow NTRB primarily because of its lead asset, AVERSA Fentanyl, which the company positions as a potential first-of-its-kind abuse-deterrent fentanyl patch for treating chronic pain. Because the product is still in development and not yet approved by the U.S. Food and Drug Administration, Nutriband is best understood as a clinical-stage, pre-revenue pharmaceutical company rather than an established commercial drugmaker. To get a sense of how it stacks up against similar names, I also checked this using Tickeron’s AI Screener.
Company Background and Operations
Nutriband Inc. was incorporated in Nevada in January 2016 and is headquartered in Orlando, Florida. The company traces its roots to Nutriband Ltd., an Irish business founded in 2012 by current Chief Executive Officer Gareth Sheridan to market transdermal patches in the health and wellness space; Nutriband Inc. acquired that Irish entity in 2016. Over time, the company's focus shifted decisively toward prescription pharmaceuticals, a pivot that began with its 2018 acquisition of 4P Therapeutics LLC and continued with the 2020 purchase of certain assets of Pocono Coated Products.
Today, Nutriband operates through two reporting segments. Pocono Pharmaceuticals (operating as Active Intelligence) provides contract development and manufacturing services for topical, transdermal, and kinesiology tape products for health, wellness, and over-the-counter customers. 4P Therapeutics performs contract research and development services for pharmaceutical and medical device clients. These segments generate the company's current, relatively small revenue stream, while its long-term growth thesis rests on its proprietary AVERSA platform.
The AVERSA Platform and Pipeline
The company's principal asset is AVERSA, an abuse-deterrent transdermal technology designed to be incorporated into existing drug patches that carry a risk of abuse, misuse, or accidental exposure. The technology applies taste- and sensory-aversive agents to a patch's backing layer in a controlled-release formulation, aiming to make oral, buccal, or inhaled abuse an unpleasant experience while leaving the underlying drug matrix unchanged. Nutriband reports that its international patent portfolio covers the AVERSA technology in roughly 46 countries, with protection extending to 2035.
The lead candidate, AVERSA Fentanyl, combines the AVERSA technology with an already-approved generic fentanyl patch intended for chronic pain management. Nutriband is developing this product under a commercial development and clinical supply agreement with Kindeva Drug Delivery (formerly 3M Drug Delivery), a contract development and manufacturing organization. The company plans to pursue a 505(b)(2) New Drug Application pathway, which would allow it to reference existing safety data for approved fentanyl. Additional pipeline candidates include AVERSA Buprenorphine and AVERSA Methylphenidate, which would apply the same abuse-deterrent approach to an opioid and a central nervous system stimulant, respectively.
Market Context and Competition
Nutriband occupies a niche position within the broader drug delivery and abuse-deterrent pharmaceutical market. Generic fentanyl patches are widely available, but the company contends that none currently carry abuse-deterrent properties, creating a potential differentiation point. Its competitive environment nevertheless includes large, well-capitalized pharmaceutical and biotechnology companies, specialty drugmakers, and other developers of abuse-deterrent technologies. As a micro-cap, pre-revenue enterprise, Nutriband has far more limited financial and commercial resources than many of these established competitors, and its future market position depends heavily on successful clinical development and eventual regulatory approval.
Why Investors Follow NTRB
Investor interest in NTRB is driven largely by the unmet need its technology targets. Abuse, diversion, and accidental pediatric exposure to opioid patches remain significant public-health concerns, and an approved abuse-deterrent fentanyl patch could address a real and persistent safety gap. The company's financial profile reflects its early stage: revenue has been modest (in the low single-digit millions annually), while the company has consistently reported net losses as it funds research and development. Investors following the name typically weigh the potential of the AVERSA platform against the substantial capital, time, and regulatory hurdles that remain before any product can reach the market.
Key Risks to Consider
Investing in Nutriband carries risks common to early-stage drug developers. The company's pharmaceutical candidates have not received FDA approval, and there is no guarantee that clinical studies will succeed or that approval will ever be granted. Nutriband has disclosed that it requires significant additional capital—well in excess of its current resources—to complete development of AVERSA Fentanyl, and it has historically relied on equity offerings and related-party financing. Regulatory changes affecting opioid prescribing, evolving FDA review timelines, and intense competition could materially affect its prospects. As a small-cap stock with limited trading volume, NTRB shares may also be subject to heightened price volatility and liquidity risk.
How Tickeron’s AI Tools Fit Into My Research
I often turn to Tickeron’s AI Screener when evaluating smaller biotech names like this one. It helps me quickly filter for technical patterns, fundamentals, and sector-specific signals that align with my own watchlist criteria, which is especially useful for comparing pre-revenue developers in the drug delivery space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NTRB's Stochastic Oscillator slumps oversold zone
The Stochastic Oscillator for NTRB moved into oversold territory on November 06, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +11.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRB advanced for three days, in 200 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRB as a result. In 85 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRB turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 40 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
NTRB moved below its 50-day moving average on November 03, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NTRB crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for NTRB entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. NTRB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.668) is normal, around the industry mean (3.498). P/E Ratio (-11.327) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (52.632) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NTRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement